Therapeutic potential of nucleic acid-based drugs in coronary hyper-proliferative vascular diseases

Current Medicinal Chemistry

Volumn 20, Issue 28, 2013, Pages 3515-3538

  Grassi, G ^a   Scaggiante, B ^a   Dapas, B ^a   Farra, R ^b   Tonon, F ^b   Lamberti, G ^c   Barba, A ^c   Fiorentino, S ^b   Fiotti, N ^a   Zanconati, F ^a   Abrami, M ^b   Grassi, M ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antisense oligonucleotides; CBG; Decoy oligonucleotides; Delivery; DNAzymes; Intima hyperplasia; Micro interfering RNAs; PTA; Ribozymes; Small interfering RNAs

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; CARDIOVASCULAR AGENT; DEOXYCHOLIC ACID; DNA; DNAZYME; DOUBLE STRANDED DNA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HAMMERHEAD RIBOZYME; LENTIVIRUS VECTOR; LIPOFECTAMINE; LIPOSOME; MICRORNA; MICROSPHERE; MIDKINE; NANOCARRIER; NANOPARTICLE; NUCLEIC ACID BASED DRUG; OLIGONUCLEOTIDE; POLYETHYLENEIMINE; POLYGLACTIN; RIBOZYME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTERY INTIMA PROLIFERATION; BIOLOGICAL FUNCTIONS; CARDIOVASCULAR RISK; CHEMICAL MODIFICATION; CORONARY STENT; DRUG ELUTING STENT; DRUG INDICATION; IN VITRO STUDY; NONHUMAN; RABBIT; RAT; RESTENOSIS; REVASCULARIZATION; REVIEW; RNA DEGRADATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 84883277841     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990031     Document Type: Review

References (177)

1. Nair, S.V.; McEwan J.R. Angina pectoris: interventional therapies and treatment of restenosis. Int. J. Biochem. Cell Biol.,2003, 35(10), 1399-1406.
2. Gruntzig, A.R.; Senning A. Siegenthaler W.E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med., 1979, 301(2), 61-68.
3. Pocock, S.J.; Henderson R.A.; Rickards A.F.; Hampton J.R.; King S.B., III; Hamm C.W.; Puel J.; Hueb W.; Goy J.J. Rodriguez A. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet, 1995, 346(8984), 1184-1189.
4. Ruygrok, P.N.; Webster, M.W.; Ardill J.J.; Chan C.C.; Mak K.H.; Meredith I.T.; Stewart J.T.; Ormiston J.A. Price S. Vessel caliber and restenosis: a prospective clinical and angiographic study of NIR stent deployment in small and large coronary arteries in the same patient.Catheter. Cardiovasc. Interv.,2003, 59(2), 165-171.
5. Califf, R.M. Restenosis: the cost to society. Am. Heart J.,1995, 130(3 Pt 2), 680-684.
6. Serruys, P.W.; de Jaegere P.; Kiemeneij F.; Macaya C.; Rutsch W.; Heyndrickx G.; Emanuelsson H.; Marco J.; Legrand V.; Materne P. . A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med.,1994, 331(8), 489-495.
7. Fischman, D.L.; Leon M.B.; Baim D.S.; Schatz R.A.; Savage M.P.; Penn I.; Detre K.; Veltri L.; Ricci D.; Nobuyoshi M. . A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med.,1994, 331(8), 496-501.
8. Fattori, R.;Piva T. Drug-eluting stents in vascular intervention. Lancet,2003, 361(9353), 247-249.
9. Moreno, R.; Fernandez C.; Alfonso F.; Hernandez R.; Perez-Vizcayno M.J.; Escaned J.; Sabate M.; Banuelos C.; Angiolillo D.J.; Azcona L. Macaya C. Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. J. Am. Coll. Cardiol.,2004, 43(11), 1964-1972.
10. Owens, G.K.; Kumar M.S. Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev.,2004, 84(3), 767-801.
11. Shoji, M.; Sata M.; Fukuda D.; Tanaka K.; Sato T.; Iso Y.; Shibata M.; Suzuki H.; Koba S.; Geshi E. Katagiri T. Temporal and spatial characterization of cellular constituents during neointimal hyperplasia after vascular injury: Potential contribution of bone-marrowderived progenitors to arterial remodeling. Cardiovasc. Pathol.,2004, 13(6), 306-312.
12. Bayes-Genis, A.; Campbell J.H.; Carlson P.J.; Holmes D.R., Jr. Schwartz R.S. Macrophages, myofibroblasts and neointimal hyperplasia after coronary artery injury and repair. Atherosclerosis,2002, 163(1), 89-98.
13. Giordano, A.; Avellino R.; Ferraro P.; Romano S.; Corcione N. Romano M.F. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. Am. J. Physiol. Heart Circ. Physiol.,2006, 290(6), H2459-H2465.
14. Papafaklis, M.I.; Chatzizisis Y.S.; Naka K.K.; Giannoglou G.D. Michalis L.K. Drug-eluting stent restenosis: effect of drug type, release kinetics, hemodynamics and coating strategy. Pharmacol. Ther.,2012, 134(1), 43-53.
15. Garg, S.;Serruys P.W. Coronary stents: current status. J. Am. Coll. Cardiol.,2010, 56(10 Suppl), S1-42.
16. Liuzzo, J.P.; Ambrose J.A. Coppola J.T. Sirolimus- and taxoleluting stents differ towards intimal hyperplasia and reendothelialization. J. Invasive Cardiol.,2005, 17(9), 497-502.
17. Moses, J.W.; Leon M.B.; Popma J.J.; Fitzgerald P.J.; Holmes D.R.; O'Shaughnessy C.; Caputo R.P.; Kereiakes D.J.; Williams D.O.; Teirstein P.S.; Jaeger J.L. Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.,2003, 349(14), 1315-1323.
18. Stone, G.W.; Ellis S.G.; Cox D.A.; Hermiller J.; O'Shaughnessy C.; Mann J.T.; Turco M.; Caputo R.; Bergin P.; Greenberg J.; Popma J.J. Russell M.E. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med.,2004, 350(3), 221-231.
19. Roiron, C.; Sanchez P.; Bouzamondo A.; Lechat P. Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart,2006, 92(5), 641-649.
20. Jukema, J.W.; Verschuren J.J.; Ahmed T.A. Quax P.H. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat. Rev. Cardiol., 2012, 9(1), 53-62.
21. Hassan, A.K.; Bergheanu S.C.; Stijnen T.; van der Hoeven B.L.; Snoep J.D.; Plevier J.W.; Schalij M.J. Wouter J.J. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur. Heart J.,2010, 31(10), 1172-1180.
22. Daemen, J.; Wenaweser P.; Tsuchida K.; Abrecht L.; Vaina S.; Morger C.; Kukreja N.; Juni P.; Sianos G.; Hellige G.; van Domburg R.T.; Hess O.M.; Boersma E.; Meier B.; Windecker S. Serruys P.W. Early and late coronary stent thrombosis of sirolimuseluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet,2007, 369(9562), 667-678.
23. Inoue, T.; Croce K.; Morooka T.; Sakuma M.; Node K. Simon D.I. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc. Interv.,2011, 4(10), 1057-1066.
24. Gahremanpour, A.; Perin E.C. Silva G. Carotid artery stenting versus endarterectomy: a systematic review. Tex. Heart Inst. J.,2012, 39(4), 474-487.
25. Muller-Hulsbeck, S.; Grimm J.; Jahnke T.; Haselbarth G. Heller M. Flow patterns from metallic vascular endoprostheses: in vitro results. Eur. Radiol.,2001, 11(5), 893-901.
26. Vernhet, H.; Demaria R.; Perez-Martin A.; Juan J.M.; Oliva-Lauraire M.C.; Marty-Double C.; Senac J.P. Dauzat M. Wall mechanics of the stented rabbit aorta: long-term study and correlation with histological findings. J. Endovasc. Ther.,2003, 10(3), 577-584.
27. Scott, N.A. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv. Drug Deliv. Rev.,2006, 58(3), 358-376.
28. Jukema, J.W.; Ahmed T.A.; Verschuren J.J. Quax P.H. Restenosis after PCI. Part 2: prevention and therapy. Nat. Rev. Cardiol.,2012, 9(2), 79-90.
29. Garg, S.;Serruys P.W. Coronary stents: looking forward. J. Am. Coll. Cardiol.,2010, 56(10 Suppl), S43-S78.
30. Birikh, K.R.; Heaton P.A. Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur. J. Biochem.,1997, 245(1), 1-16.
31. Grassi, M.; Cavallaro G.; Scirè S.; Scaggiante B.; Daps B.; Farra R.; Baiz D.; Giansante C.; Guarnieri G.; Perin D. Grassi G. Current Strategies to Improve the Efficacy and the Delivery of Nucleic Acid Based Drugs.Curr. Signal Trans. Ther.,2010, 5(2), 92-120.
32. Grassi, G.; Dawson P.; Guarnieri G.; Kandolf R. Grassi M. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases. Curr. Pharm. Biotechnol.,2004, 5(4), 369-386.
33. Symons, R.H. Small catalytic RNAs. Annu. Rev. Biochem.,1992, 61 (641-671.
34. Hart, C.E.; Forstrom J.W.; Kelly J.D.; Seifert R.A.; Smith R.A.; Ross R.; Murray M.J. Bowen-Pope D.F. Two classes of PDGF receptor recognize different isoforms of PDGF. Science,1988, 240(4858), 1529-1531.
35. Kotani, M.; Fukuda N.; Ando H.; Hu W.Y.; Kunimoto S.; Saito S. Kanmatsuse K. Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury. Cardiovasc. Res.,2003, 57(1), 265-276.
36. Yamamoto, K.; Morishita R.; Tomita N.; Shimozato T.; Nakagami H.; Kikuchi A.; Aoki M.; Higaki J.; Kaneda Y. Ogihara T. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation,2000, 102(11), 1308-1314.
37. Nikol, S.; Isner J.M.; Pickering J.G.; Kearney M.; Leclerc G. Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J. Clin. Invest.,1992, 90(4), 1582-1592.
38. Jarvis, T.C.; Wincott F.E.; Alby L.J.; McSwiggen J.A.; Beigelman L.; Gustofson J.; DiRenzo A.; Levy K.; Arthur M.; Matulic-Adamic J.; Karpeisky A.; Gonzalez C.; Woolf T.M.; Usman N. Stinchcomb D.T. Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J. Biol. Chem.,1996, 271(46), 29107-29112.
39. Jarvis, T.C.; Alby L.J.; Beaudry A.A.; Wincott F.E.; Beigelman L.; McSwiggen J.A.; Usman N. Stinchcomb D.T. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave cmyb mRNA. RNA,1996, 2(5), 419-428.
40. Alitalo, K.; Winqvist R.; Lin C.C.; de la C.A.; Schwab M. Bishop J.M. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc. Natl. Acad. Sci. USA,1984, 81(14), 4534-4538.
41. Macejak, D.G.; Lin H.; Webb S.; Chase J.; Jensen K.; Jarvis T.C.; Leiden J.M. Couture L. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo. J. Virol.,1999, 73(9), 7745-7751.
42. Frimerman, A.; Welch P.J.; Jin X.; Eigler N.; Yei S.; Forrester J.; Honda H.; Makkar R.; Barber J. Litvack F. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation, 1999, 99(5), 697-703.
43. Fairman, M.P. DNA polymerase delta/PCNA: actions and interactions. J. Cell Sci.,1990, 95 (Pt 1) (1-4.
44. Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev.,1998, 12(15), 2245-2262.
45. Ohtsubo, M.; Theodoras A.M.; Schumacher J.; Roberts J.M. Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell Biol.,1995, 15(5), 2612-2624.
46. Geng, Y.; Eaton E.N.; Picon M.; Roberts J.M.; Lundberg A.S.; Gifford A.; Sardet C. Weinberg R.A. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene,1996, 12(6), 1173-1180.
47. Grassi, G.; Grassi M.; Platz J.; Bauriedel G.; Kandolf R. Kuhn A. Selection and characterization of active hammerhead ribozymes targeted against cyclin E and E2F1 full-length mRNA. Antisense Nucleic Acid Drug Dev., 2001, 11(5), 271-287.
48. Grassi, G.; Schneider A.; Engel S.; Racchi G.; Kandolf R. Kuhn A. Hammerhead ribozymes targeted against cyclin E and E2F1 cooperate to down regulate coronary smooth muscle cells proliferation. J. Gene Med., 2005, 7(1223-1234.
49. Perlman, H.; Sata M.; Krasinski K.; Dorai T.; Buttyan R. Walsh K. Adenovirus-encoded hammerhead ribozyme to Bcl-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis. Cardiovasc. Res., 2000, 45(3), 570-578.
50. Gu, J.L.; Veerapanane D.; Rossi J.; Natarajan R.; Thomas L. Nadler J. Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygenase in porcine aortic vascular smooth muscle cells.Circ. Res., 1995, 77(1), 14-20.
51. Gu, J.L.; Pei H.; Thomas L.; Nadler J.L.; Rossi J.J.; Lanting L. Natarajan R. Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation, 2001, 103(10), 1446-1452.
52. Ellington, A.D.;Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287), 818-822.
53. Santoro, S.W.;Joyce G.F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA, 1997, 94(9), 4262-4266.
54. Achenbach, J.C.; Chiuman W.; Cruz R. Li Y. DNAzymes:from creation in vitro to application in vivo.Curr. Pharmaceut. Biotechnol., 2004, 5(4), 321-336.
55. Santiago, F.S.; Lowe H.C.; Kavurma M.M.; Chesterman C.N.; Baker A.; Atkins D.G. Khachigian L.M. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med., 1999, 5(11), 1264-1269.
56. Khachigian, L.M.; Lindner V.; Williams A.J. Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science, 1996, 271(5254), 1427-1431.
57. Lowe, H.C.; Fahmy R.G.; Kavurma M.M.; Baker A.; Chesterman C.N. Khachigian L.M. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ. Res., 2001, 89(8), 670-677.
58. Khachigian, L.M.; Fahmy R.G.; Zhang G.; Bobryshev Y.V. Kaniaros A. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J. Biol. Chem., 2002, 277(25), 22985-22991.
59. Pirollo, K.F.; Rait A.; Sleer L.S. Chang E.H. Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther., 2003, 99(1), 55-77.
60. Wu, H.; Lima W.F.; Zhang H.; Fan A.; Sun H. Crooke S.T. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 2004, 279(17), 17181-17189.
61. Morishita, R.; Gibbons G.H.; Ellison K.E.; Nakajima M.; Zhang L.; Kaneda Y.; Ogihara T. Dzau V.J. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA, 1993, 90(18), 8474-8478.
62. Morishita, R.; Gibbons G.H.; Ellison K.E.; Nakajima M.; von der L.H.; Zhang L.; Kaneda Y.; Ogihara T. Dzau V.J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest., 1994, 93(4), 1458-1464.
63. Cioffi, C.L.; Garay M.; Johnston J.F.; McGraw K.; Boggs R.T.; Hreniuk D. Monia B.P. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol. Pharmacol., 1997, 51(3), 383-389.
64. Pollman, M.J.; Hall J.L.; Mann M.J.; Zhang L. Gibbons G.H. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease.Nat Med, 1998, 4(2), 222-227.
65. Li, D.; Ma S.; Yang Y.; Yang D.; Li G.; Zhang X.; Zhu J.; Sun M. Tang B. BTEB2 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model. Mol. Med. Report, 2011, 4(3), 413-417.
66. Simons, M.; Edelman E.R.; DeKeyser J.L.; Langer R. Rosenberg R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature, 1992, 359(6390), 67-70.
67. Bennett, M.R.; Anglin S.; McEwan J.R.; Jagoe R.; Newby A.C. Evan G.I. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest., 1994, 93(2), 820-828.
68. Kutryk, M.J.; Foley D.P.; van den Brand M.; Hamburger J.N.; van der Giessen W.J.; deFeyter P.J.; Bruining N.; Sabate M. Serruys P.W. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol., 2002, 39(2), 281-287.
69. Kipshidze, N.N.; Kim H.S.; Iversen P.; Yazdi H.A.; Bhargava B.; New G.; Mehran R.; Tio F.; Haudenschild C.; Dangas G.; Stone G.W.; Iyer S.; Roubin G.S.; Leon M.B. Moses J.W. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J. Am. Coll. Cardiol., 2002, 39(10), 1686-1691.
70. Kipshidze, N.; Iversen P.; Overlie P.; Dunlap T.; Titus B.; Lee D.; Moses J.; O'Hanley P.; Lauer M. Leon M.B. First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. Cardiovasc. Revasc. Med., 2007, 8(4), 230-235.
71. Lee, I.K.; Ahn J.D.; Kim H.S.; Park J.Y. Lee K.U. Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation. Curr. Drug Targets, 2003, 4(8), 619-623.
72. Yoshimura, S.; Morishita R.; Hayashi K.; Yamamoto K.; Nakagami H.; Kaneda Y.; Sakai N. Ogihara T. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using ciselement 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther., 2001, 8(21), 1635-1642.
73. Miyake, T.; Aoki M.; Shiraya S.; Tanemoto K.; Ogihara T.; Kaneda Y. Morishita R. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J. Mol. Cell Cardiol., 2006, 41(3), 431-440.
74. Murrell, M.; Khachigian L.M. Ward M.R. Divergent roles of NFkappaB and Egr-1 in flow-dependent restenosis after angioplasty and stenting. Atherosclerosis, 2011, 214(1), 65-72.
75. Yamasaki, K.; Asai T.; Shimizu M.; Aoki M.; Hashiya N.; Sakonjo H.; Makino H.; Kaneda Y.; Ogihara T. Morishita R. Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther., 2003, 10(4), 356-364.
76. Egashira, K.; Suzuki J.; Ito H.; Aoki M.; Isobe M. Morishita R. Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J. Gene Med., 2008, 10(7), 805-809.
77. Suzuki, J.; Tezuka D.; Morishita R. Isobe M. An initial case of suppressed restenosis with nuclear factor-kappa B decoy transfection after percutaneous coronary intervention. J. Gene Med., 2009, 11(1), 89-91.
78. Morishita, R.; Gibbons G.H.; Horiuchi M.; Ellison K.E.; Nakama M.; Zhang L.; Kaneda Y.; Ogihara T. Dzau V.J. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA, 1995, 92(13), 5855-5859.
79. Hashiya, N.; Aoki M.; Tachibana K.; Taniyama Y.; Yamasaki K.; Hiraoka K.; Makino H.; Yasufumi K.; Ogihara T. Morishita R. Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model. Biochem. Biophys. Res. Commun., 2004, 317(2), 508-514.
80. Nakamura, T.; Morishita R.; Asai T.; Tsuboniwa N.; Aoki M.; Sakonjo H.; Yamasaki K.; Hashiya N.; Kaneda Y. Ogihara T. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Gene Ther., 2002, 9(8), 488-494.
81. Alexander, J.H.; Hafley G.; Harrington R.A.; Peterson E.D.; Ferguson T.B., Jr.; Lorenz T.J.; Goyal A.; Gibson M.; Mack M.J.; Gennevois D.; Califf R.M. Kouchoukos N.T. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA, 2005, 294(19), 2446-2454.
82. Conte, M.S.; Bandyk D.F.; Clowes A.W.; Moneta G.L.; Seely L.; Lorenz T.J.; Namini H.; Hamdan A.D.; Roddy S.P.; Belkin M.; PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg., 2006, 43(4), 742-751.
83. Giangrande, P.H.; Zhang J.; Tanner A.; Eckhart A.D.; Rempel R.E.; Andrechek E.R.; Layzer J.M.; Keys J.R.; Hagen P.O.; Nevins J.R.; Koch W.J. Sullenger B.A. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc. Natl. Acad. Sci. USA, 2007, 104(32), 12988-12993.
84. Miyake, T.; Aoki M. Morishita R. Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model. Cardiovasc. Res., 2008, 79(4), 706-714.
85. Ohtani, K.; Egashira K.; Usui M.; Ishibashi M.; Hiasa K.I.; Zhao Q.; Aoki M.; Kaneda Y.; Morishita R. Takeshita A. Inhibition of neointimal hyperplasia after balloon injury by cis-element 'decoy' of early growth response gene-1 in hypercholesterolemic rabbits. Gene Ther., 2004, 11(2), 126-132.
86. Han, W.;Liu G.N. EGR-1 decoy ODNs inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of ballooninjured arteries in rat. Life Sci., 2010, 86(7-8), 234-243.
87. Ahn, J.D.; Morishita R.; Kaneda Y.; Lee S.J.; Kwon K.Y.; Choi S.Y.; Lee K.U.; Park J.Y.; Moon I.J.; Park J.G.; Yoshizumi M.; Ouchi Y. Lee I.K. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ. Res., 2002, 90(12), 1325-1332.
88. Kume, M.; Komori K.; Matsumoto T.; Onohara T.; Takeuchi K.; Yonemitsu Y. Sugimachi K. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation, 2002, 105(10), 1226-1232.
89. Buchwald, A.B.; Wagner A.H.; Webel C. Hecker M. Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs. J. Am. Coll. Cardiol., 2002, 39(4), 732-738.
90. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2), 281-297.
91. Kurreck, J. Proof of RNA interference in humans after systemic delivery of siRNAs. Angew. Chem. Int. Ed. Engl., 2010, 49(36), 6258-6259.
92. Kurreck, J. RNA interference: from basic research to therapeutic applications. Angew. Chem. Int. Ed. Engl., 2009, 48(8), 1378-1398.
93. Carthew, R.W.;Sontheimer E.J. Origins and Mechanisms of miRNAs and siRNAs. Cell, 2009, 136(4), 642-655.
94. Sharp, P.A. RNA interference - 2001. Genes Dev., 2001, 15(5), 485-490.
95. Scaggiante, B.; Dapas B.; Farra R.; Grassi M.; Pozzato G.; Giansante C.; Fiotti N. Grassi G. Improving siRNA bio-distribution and minimizing side effects. Curr. Drug Metab., 2011, 12, 11-23.
96. Banno, H.; Takei Y.; Muramatsu T.; Komori K. Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J. Vasc. Surg., 2006, 44(3), 633-641.
97. Qu, Y.; Shi X.; Zhang H.; Sun W.; Han S.; Yu C. Li J. VCAM-1 siRNA reduces neointimal formation after surgical mechanical injury of the rat carotid artery. J. Vasc. Surg., 2009, 50(6), 1452-1458.
98. Dapas, B.; Farra R.; Grassi M.; Giansante C.; Fiotti N.; Uxa L.; Rainaldi G.; Mercatanti A.; Colombatti A.; Spessotto P.; Lacovich V.; Guarnieri G. Grassi G. Role of E2F1-cyclinE1-cyclinE2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its down regulation by siRNAs. Mol. Med., 2009, 15(9-10), 297-306.
99. Werth, D.; Grassi G.; Konjer N.; Dapas B.; Farra R.; Giansante C.; Kandolf R.; Guarnieri G.; Nordheim A. Heidenreich O. Proliferation of human primary vascular smooth muscle cells depends on serum response factor. Eur. J. Cell Biol., 2010, 89(2-3), 216-224.
100. Song, Y.;Yang Z. CIAPIN1 siRNA inhibits vascular smooth muscle cell proliferation and migration to promote apoptosis by regulating Bcl-2 and Bax. Curr. Neurovasc. Res., 2012.
101. Sun, J.; Zheng J.; Ling K.H.; Zhao K.; Xie Z.; Li B.; Wang T.; Zhu Z.; Patel A.N.; Min W.; Liu K. Zheng X. Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA. J. Transl. Med., 2012, 10, 2.
102. Zuojun, H.; Lingyu H.; Wei H.; Henghui Y.; Chonggang Z.; Jingsong W.; Mian W.; Yong L. Shenming W. Interference of IP-10 expression inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in carotid artery: a new insight in the prevention of restenosis. Cell Biochem. Biophys., 2012, 62(1), 125-135.
103. Singh, N.K.; Kundumani-Sridharan V.; Kumar S.; Verma S.K.; Kotla S.; Mukai H.; Heckle M.R. Rao G.N. Protein kinase N1 is a novel substrate of NFATc1-mediated cyclin D1-CDK6 activity and modulates vascular smooth muscle cell division and migration leading to inward blood vessel wall remodeling. J. Biol. Chem., 2012, 287(43), 36291-36304.
104. Berglund, L.M.; Kotova O.; Osmark P.; Grufman H.; Xing C.; Lydrup M.L.; Goncalves I.; Autieri M.V. Gomez M.F. NFAT regulates the expression of AIF-1 and IRT-1: yin and yang splice variants of neointima formation and atherosclerosis. Cardiovasc. Res., 2012, 93(3), 414-423.
105. Aubart, F.C.; Sassi Y.; Coulombe A.; Mougenot N.; Vrignaud C.; Leprince P.; Lechat P.; Lompre A.M. Hulot J.S. RNA interference targeting STIM1 suppresses vascular smooth muscle cell proliferation and neointima formation in the rat. Mol. Ther., 2009, 17(3), 455-462.
106. Yang, J.; Jiang H.; Chen S.S.; Chen J.; Li W.Q.; Xu S.K. Wang J.C. Lentivirus-mediated RNAi targeting CREB binding protein attenuates neointimal formation and promotes re-endothelialization in balloon injured rat carotid artery. Cell Physiol. Biochem., 2010, 26(3), 441-448.
107. Matsumae, H.; Yoshida Y.; Ono K.; Togi K.; Inoue K.; Furukawa Y.; Nakashima Y.; Kojima Y.; Nobuyoshi M.; Kita T. Tanaka M. CCN1 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model. Arterioscler. Thromb. Vasc. Biol., 2008, 28(6), 1077-1083.
108. Chen, L.J.; Lim S.H.; Yeh Y.T.; Lien S.C. Chiu J.J. Roles of microRNAs in atherosclerosis and restenosis. J. Biomed. Sci., 2012, 19(1), 79.
109. Ji, R.; Cheng Y.; Yue J.; Yang J.; Liu X.; Chen H.; Dean D.B. Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res., 2007, 100(11), 1579-1588.
110. Liu, X.; Cheng Y.; Zhang S.; Lin Y.; Yang J. Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ. Res., 2009, 104(4), 476-487.
111. Liu, X.; Cheng Y.; Yang J.; Xu L. Zhang C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J. Mol. Cell Cardiol., 2012, 52(1), 245-255.
112. Iaconetti, C.; Polimeni A.; Sorrentino S.; Sabatino J.; Pironti G.; Esposito G.; Curcio A. Indolfi C. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res. Cardiol., 2012, 107(5), 296.
113. Geary, R.S.; Yu R.Z. Levin A.A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs, 2001, 2(4), 562-573.
114. Watanabe, T.A.; Geary R.S. Levin A.A. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides, 2006, 16(2), 169-180.
115. Amarzguioui, M.; Holen T.; Babaie E. Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res., 2003, 31(2), 589-595.
116. Hall, A.H.; Wan J.; Shaughnessy E.E.; Ramsay S.B. Alexander K.A. RNA interference using boranophosphate siRNAs: structureactivity relationships. Nucleic Acids Res., 2004, 32(20), 5991-6000.
117. Schwarz, D.S.; Tomari Y. Zamore P.D. The RNA-induced silencing complex is a Mg2+-dependent endonuclease. Curr. Biol., 2004, 14(9), 787-791.
118. Choung, S.; Kim Y.J.; Kim S.; Park H.O. Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun., 2006, 342(3), 919-927.
119. Martin, P. A New Access to 2-O-Alkylated Ribonucleosides and Properties of 2-O-Alkylated Oligoribonucleotides. Helvetica Chim. Acta, 1995, 78 (486-504.
120. Weiler, J.; Hunziker J. Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther., 2006, 13(6), 496-502.
121. Chiu, Y.L.;Rana T.M. siRNA function in RNAi: a chemical modification analysis. RNA, 2003, 9(9), 1034-1048.
122. Blidner, R.A.; Hammer R.P.; Lopez M.J.; Robinson S.O. Monroe W.T. Fully 2′-deoxy-2′-fluoro substituted nucleic acids induce RNA interference in mammalian cell culture. Chem. Biol. Drug Des., 2007, 70(2), 113-122.
123. Layzer, J.M.; McCaffrey A.P.; Tanner A.K.; Huang Z.; Kay M.A. Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA, 2004, 10(5), 766-771.
124. Hoshika, S.; Minakawa N.; Kamiya H.; Harashima H. Matsuda A. RNA interference induced by siRNAs modified with 4′-thioribonucleosides in cultured mammalian cells. FEBS Lett., 2005, 579(14), 3115-3118.
125. Dande, P.; Prakash T.P.; Sioufi N.; Gaus H.; Jarres R.; Berdeja A.; Swayze E.E.; Griffey R.H. Bhat B. Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications. J. Med. Chem., 2006, 49(5), 1624-1634.
126. Petersen, M.;Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol., 2003, 21(2), 74-81.
127. Elmen, J.; Thonberg H.; Ljungberg K.; Frieden M.; Westergaard M.; Xu Y.; Wahren B.; Liang Z.; Orum H.; Koch T. Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res., 2005, 33(1), 439-447.
128. Hornung, V.; Guenthner-Biller M.; Bourquin C.; Ablasser A.; Schlee M.; Uematsu S.; Noronha A.; Manoharan M.; Akira S.; de Fougerolles A.; Endres S. Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med., 2005, 11(3), 263-270.
129. Wahlestedt, C.; Salmi P.; Good L.; Kela J.; Johnsson T.; Hokfelt T.; Broberger C.; Porreca F.; Lai J.; Ren K.; Ossipov M.; Koshkin A.; Jakobsen N.; Skouv J.; Oerum H.; Jacobsen M.H. Wengel J. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA, 2000, 97(10), 5633-5638.
130. Jepsen, J.S.; Pfundheller H.M. Lykkesfeldt A.E. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides, 2004, 14(2), 147-156.
131. Nielsen P, Egholm M, Berg R, Buchardt O. Peptide nucleic acids (PNA) : oligonucleotide analogs with a polyamide backbone. In: Crooke S, Lebleu B, eds. Antisense Research and Applications. Boca Rato, FL: CRC Press, 1993, 363-73.
132. Summerton, J.;Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev., 1997, 7(3), 187-195.
133. Arora, V.; Hannah T.L.; Iversen P.L. Brand R.M. Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm. Res., 2002, 19(10), 1465-1470.
134. Iversen, P.L.; Arora V.; Acker A.J.; Mason D.H. Devi G.R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res., 2003, 9(7), 2510-2519.
135. Fletcher, S.; Honeyman K.; Fall A.M.; Harding P.L.; Johnsen R.D. Wilton S.D. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med., 2006, 8(2), 207-216.
136. Osako, M.K.; Tomita N.; Nakagami H.; Kunugiza Y.; Yoshino M.; Yuyama K.; Tomita T.; Yoshikawa H.; Ogihara T. Morishita R. Increase in nuclease resistance and incorporation of NF-kappaB decoy oligodeoxynucleotides by modification of the 3′-terminus. J. Gene Med., 2007, 9(9), 812-819.
137. Giacca, M.;Zacchigna S. Virus-mediated gene delivery for human gene therapy. J. Control Release, 2012, 161(2), 377-388.
138. Miller, A.D. Cationic Liposomes for Gene Therapy. Angew. Chem. Int. Ed., 1998, 37, 1768-1785.
139. Friend, D.S.; Papahadjopoulos D. Debs R.J. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta, 1996, 1278(1), 41-50.
140. Sun, J.; Zheng J.; Ling K.H.; Zhao K.; Xie Z.; Li B.; Wang T.; Zhu Z.; Patel A.N.; Min W.; Liu K. Zheng X. Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA. J. Transl. Med., 2012, 10, 2.
141. Huang, S.L. Liposomes in ultrasonic drug and gene delivery. Adv. Drug Deliv. Rev., 2008, 60(10), 1167-1176.
142. Husseini, G.A.;Pitt W.G. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv. Drug Deliv. Rev., 2008, 60(10), 1137-1152.
143. Nyborg, W.L. Ultrasound, contrast agents and biological cells; a simplified model for their interaction during in vitro experiments. Ultrasound Med. Biol., 2006, 32(10), 1557-1568.
144. Laing, S.T.; Kim H.; Kopechek J.A.; Parikh D.; Huang S.; Klegerman M.E.; Holland C.K. McPherson D.D. Ultrasound-mediated delivery of echogenic immunoliposomes to porcine vascular smooth muscle cells in vivo. J. Liposome Res., 2010, 20(2), 160-167.
145. Huang, S.L.; Kee P.H.; Kim H.; Moody M.R.; Chrzanowski S.M.; MacDonald R.C. McPherson D.D. Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia. J. Am. Coll. Cardiol., 2009, 54(7), 652-659.
146. Abbas, A.O.; Donovan M.D. Salem A.K. Formulating poly(lactideco- glycolide) particles for plasmid DNA delivery. J. Pharm. Sci., 2008, 97(7), 2448-2461.
147. Panyam, J.; Zhou W.Z.; Prabha S.; Sahoo S.K. Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J., 2002, 16(10), 1217-1226.
148. Yang, J.; Zeng Y.; Li Y.; Song C.; Zhu W.; Guan H. Li X. Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis. Eur. J. Pharm. Sci., 2008, 35(5), 427-434.
149. Park, T.G.; Jeong J.H. Kim S.W. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev., 2006, 58(4), 467-486.
150. Lee, H.; Jeong J.H. Park T.G. A new gene delivery formulation of polyethylenimine/DNA complexes coated with PEG conjugated fusogenic peptide. J. Control Release, 2001, 76(1-2), 183-192.
151. Kim, D.; Lee D.; Jang Y.L.; Chae S.Y.; Choi D.; Jeong J.H. Kim S.H. Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells. Eur. J. Pharm. Biopharm., 2012, 81(1), 14-23.
152. Li, J.M.; Newburger P.E.; Gounis M.J.; Dargon P.; Zhang X. Messina L.M. Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model. Gene Ther., 2010, 17(10), 1279-1287.
153. Pierige, F.; Serafini S.; Rossi L. Magnani M. Cell-based drug delivery. Adv. Drug Deliv. Rev., 2008, 60(2), 286-295.
154. Magnani, M.; Pierige F. Rossi L. Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acid-based therapeutics. Ther. Deliv., 2012, 3(3), 405-414.
155. Lande, C.; Cecchettini A.; Tedeschi L.; Taranta M.; Naldi I.; Citti L.; Trivella M.G.; Grimaldi S. Cinti C. Innovative erythrocytebased carriers for gene delivery in porcine vascular smooth muscle cells: basis for local therapy to prevent restenosis. Cardiovasc. Hematol. Disord. Drug Targets, 2012, 12(1), 68-75.
156. Chorny, M.; Fishbein I. Golomb G. Drug delivery systems for the treatment of restenosis. Crit. Rev. Ther. Drug Carrier Syst., 2000, 17(3), 249-284.
157. Sharma, S.; Christopoulos C.; Kukreja N. Gorog D.A. Local drug delivery for percutaneous coronary intervention. Pharmacol. Ther., 2011, 129(3), 260-266.
158. Kumamoto, M.; Nakashima Y. Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum. Pathol., 1995, 26(4), 450-456.
159. Shi, Y.; O'Brien J.E.; Fard A.; Mannion J.D.; Wang D. Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation, 1996, 94(7), 1655-1664.
160. Smolock, E.M.; Korshunov V.A.; Glazko G.; Qiu X.; Gerloff J. Berk B.C. Ribosomal Protein L17, RpL17, is an Inhibitor of Vascular Smooth Muscle Growth and Carotid Intima Formation. Circulation, 2012, 126(20), 2418-2427.
161. West, J.L.;Hubbell J.A. Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing. Proc. Natl. Acad. Sci. USA, 1996, 93(23), 13188-13193.
162. Slepian MJ;Hubbel JA. Polymeric endoluminal gel paving: hydrogel systems for local barrier creation and site specific drug delivery. Adv. Drug Deliv. Rev., 1997, 24, 11-30.
163. Grassi, G.; Farra R.; Noro E.; Voinovic D.; Lapasin R; Dapas B.; Alpar O.; Zennaro C.; Carraro M.; Giansante C.; Guarnieri G.; Pascotto A.; Rehimers B. Grassi M. Charactherization of nucleid acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices. J. Drug Deliv. Sci. Technol., 2007, 17(5), 325-331.
164. Grassi, G.; Crevatin A.; Farra R.; Guarnieri G.; Pascotto A.; Rehimers B.; Lapasin R. Grassi M. Rheological properties of aqueous Pluronic-alginate systems containing liposomes. J. Colloid. Interface Sci., 2006, 301(1), 282-290.
165. Davia, L.; Grassi G.; Pontrelli G.; Lapasin R.; Perin D. Grassi M. Mathematical modelling of NABD release from endoluminal gel paved stent. Comput. Biol. Chem., 2009, 33 (33-40.
166. Barba AA, d'Amore M, Grassi M, Chirico S, Lamberti G, Titomanlio G. Investigation of Pluronic© F127-Water solutions phase transitions by DSC and dielectric spectroscopy. J. Applied Polymer Sci., 2009, 114(2), 688-695.
167. Barba AA, Lamberti G, Rabbia L, Grassi M, Larobina D, Grassi G. Modeling of the reticulation kinetics of alginate/pluronic blends for biomedical applications, submitted for publication to Polymer. 2013, submitted for pubblication 2013.
168. Dalmoro A, Barba AA, Lamberti G, Grassi M, d'Amore M. Pharmaceutical applications of biocompatible polymer blends containing sodium alginate. Adv. Polymer Technol., 31(3), 219-230. 2012.
169. Livnat, M.; Beyar R. Seliktar D. Endoluminal hydrogel films made of alginate and polyethylene glycol: physical characteristics and drug-eluting properties. J. Biomed. Mater. Res. A, 2005, 75(3), 710-722.
170. Labhasetwar, V.; Song C. Levy R. Nanoparticles drug delivery system for restenosis. Adv. Drug Deliv. Rev., 1997, 24 (63-85.
171. Che, H.L.; Bae I.H.; Lim K.S.; Song I.T.; Lee H.; Muthiah M.; Namgung R.; Kim W.J.; Kim D.G.; Ahn Y.; Jeong M.H. Park I.K. Suppression of post-angioplasty restenosis with an Akt1 siRNAembedded coronary stent in a rabbit model. Biomaterials, 2012, 33(33), 8548-8556.
172. Paul, A.; Shao W.; Shum-Tim D. Prakash S. The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNA(Ang1+Vegf) nanoparticles. Biomaterials, 2012, 33(30), 7655-7664.
173. Zhu, D.; Jin X.; Leng X.; Wang H.; Bao J.; Liu W.; Yao K. Song C. Local gene delivery via endovascular stents coated with dodecylated chitosan-plasmid DNA nanoparticles. Int. J. Nanomedicine, 2010, 5, 1095-1102.
174. Malmo, J.; Sorgard H.; Varum K.M. Strand S.P. siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing. J. Control. Release, 2012, 158(2), 261-268.
175. Schneider, B.; Grote M.; John M.; Haas A.; Bramlage B.; Lckenstein L.M.; Jahn-Hofmann K.; Bauss F.; Cheng W.; Croasdale R.; Daub K.; Dill S.; Hoffmann E.; Lau W.; Burtscher H.; Ludtke J.L.; Metz S.; Mundigl O.; Neal Z.C.; Scheuer W.; Stracke J.; Herweijer H. Brinkmann U. Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies. Mol. Ther. Nucleic Acids, 2012, 1, e46.
176. Kenjo, E.; Asai T.; Yonenaga N.; Ando H.; Ishii T.; Hatanaka K.; Shimizu K.; Urita Y.; Dewa T.; Nango M.; Tsukada H. Oku N. Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy. Biol. Pharm. Bull., 2013, 36(2), 287-291.
177. Serruys, P.W.; Sianos G.; Abizaid A.; Aoki J.; den H.P.; Bonnier H.; Smits P.; McClean D.; Verheye S.; Belardi J.; Condado J.; Pieper M.; Gambone L.; Bressers M.; Symons J.; Sousa E. Litvack F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J. Am. Coll. Cardiol., 2005, 46(2), 253-260.